Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Registration Number
- NCT02172781
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 36
Inclusion Criteria
All participants in the study should be healthy males, ranging from 40 to 65 years of age and within ±20% of their normal weight (Broca-Index)
Each subject will have his medical history taken and will receive a complete medical examination (including blood pressure and pulse rate measurements) as well as a 12-lead ECG.
Haematological, hepatic and renal function tests will be carried out in the laboratory (Bioscentia GmbH, FRG). The subjects will fast for 8 hours before collection of specimens for all laboratory evaluations. The above mentioned examinations will be performed within 14 days before the first drug administration.
In accordance with Good Clinical Practice (GCP) and local legislation all subjects will have given their written informed consent prior to admission to the study.
Following inclusion criteria were of special interest for this study:
- Normal spirometry as evidenced by a baseline FEV1 ≥ 80% of predicted normal value for age, height and sex. Predicted normal values will be calculated according to European Community of Coal and Steel (ECCS)
- Ability to perform technically satisfactory pulmonary function tests.
Read More
Exclusion Criteria
- Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance.
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
- History of orthostatic hypotension, fainting spells or blackouts.
- Chronic or relevant acute infections.
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator.
- Intake of drugs with a long half-life (≥ 24hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study.
- Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study, among these all non-selective beta blockers, oral beta adrenergics or long-acting beta-adrenergics such as salmeterol and formoterol, and anticholinergic drugs including ATROVENT ®(ipratropium) by oral inhalation and ATROVENT® Nasal Spray.
- Participation in another trial with an investigational drug (≤ two months prior to administration or during trial).
- Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- Inability to refrain from smoking on trial days.
- Alcohol abuse (> 60g/day)
- Drug abuse
- Blood donation (≥ 100 ml within four weeks prior to administration or during the trial)
- Any laboratory value outside the clinically accepted reference range.
- Excessive physical activities (within the last week before and during the study)
Following exclusion criteria are of special interest for the study:
- Subjects with known hypersensitivity to anticholinergic drugs.
- Subjects with known symptomatic prostatic hypertrophy or bladder neck obstruction
- Subjects with known narrow-angle glaucoma
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo matching tiotropium - inhalation capsule Placebo matching tiotropium - Placebo matching tiotropium - inhalation capsule Placebo matching ipratropium - Placebo matching to ipratropium - unit dose vial Ipratropium - unit dose vial - Ipratropium - unit dose vial Ipratropium - unit dose vial - Ipratropium - unit dose vial Placebo matching ipratropium - Tiotropium - inhalation capsule - low dose Ipratropium - unit dose vial - Tiotropium - inhalation capsule - low dose Placebo matching tiotropium - Tiotropium - inhalation capsule - low dose Placebo matching ipratropium - Placebo matching to ipratropium - unit dose vial Placebo matching tiotropium - Placebo matching to ipratropium - unit dose vial Placebo matching ipratropium - Tiotropium - inhalation capsule - high dose Ipratropium - unit dose vial - Tiotropium - inhalation capsule - high dose Placebo matching ipratropium - Placebo matching tiotropium - inhalation capsule Ipratropium - unit dose vial - Placebo matching tiotropium - inhalation capsule Tiotropium - inhalation capsule - Placebo matching to ipratropium - unit dose vial Tiotropium - inhalation capsule - Tiotropium - inhalation capsule - high dose Tiotropium - inhalation capsule - Tiotropium - inhalation capsule - low dose Tiotropium - inhalation capsule -
- Primary Outcome Measures
Name Time Method AUC - Area under the curve of the log-transformed value of salivary secretion after application of randomised treatment over the interval from two hours to six hours on study day 19 and 22
- Secondary Outcome Measures
Name Time Method Cmax (Peak (maximum) plasma concentration) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Cmax,ss (maximum observed concentration of the analyte in plasma at steady state) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Tmax (time to reach the peak plasma concentration) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Tmax, ss (Time to reach maximum concentration of the analyte in plasma at steady state) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Cpre (predose concentration of the analyte in plasma) -Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Cpre,ss (predose concentration of the analyte in plasma at steady state) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) AUC (area under the concentration time curve of the analyte in plasma) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) AUC,ss (area under the concentration time curve of the analyte in plasma at steady state) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Ae (amount of analyte that is eliminated in urine) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) CLR (renal clearance of the analyte) - Tiotropium Day1, day 7, day 19, day 22 ( before and different time points after dosing), day 2, day 3, day 20 (before dosing) Cmax (Peak (maximum) plasma concentration) - Ipratropium Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) Tmax (time to reach the peak plasma concentration) - Ipratropium Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) AUC (area under the concentration time curve of the analyte in plasma) - Ipratropium Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) Ae (amount of analyte that is eliminated in urine) - Ipratropium Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) CLR (renal clearance of the analyte) - Ipratropium Day A1, A4 (before and after inhalation of ipratropium), day 19, day 22 (before, at end of ipratropium inhalation and different time points after tiotropium dosing), day 20 (10 min.before tiotropium dosing) Amount of Salivary secretion Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 FEV1 (Forced expiratory volume in one second) Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 FVC (Forced vital capacity) Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 MMEF25-75% (maximal mid-expiratory flow) Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 PEFR (peak expiratory flow rate) Screening, A1, A4 ( before and after dosing of ipratropium), different time points at day 1, day 2, day 7, day 19 and 22 (before and after dosing of tiotropium and Ipratropium), day 20, day 23 Occurence of adverse events Screening, A1-A6, B1-B23, end of study (within 8 days after last dosing tiotropium)